Inside Ginkgo's SPAC deal

Advertisement
Inside Ginkgo's SPAC deal
A biological engineer aliquots cells, separating out some of the material, at Ginkgo Bioworks.Jessica Rinaldi/The Boston Globe via Getty Images

Hello,

Welcome to Insider Healthcare. I'm Lydia Ramsey Pflanzer, and today in healthcare news:

If you're new to this newsletter, sign up here. Comments, tips? Email me at lramsey@insider.com or tweet @lydiaramsey125. Let's get to it...

Advertisement

Ginkgo Bioworks is playing to investors hunting for the next Amazon. But 2 experts say the biotech is overvalued and overambitious.

Get the full story>>


Inside Ginkgo's SPAC deal
Christopher Gartin, left, and Prianka Verma, rightLinkedIn/Deutsche Bank

Here's which Wall Street banks are snapping up healthcare dealmakers in what one headhunter calls an 'extremely, extremely active' hiring market

  • Healthcare investment bankers are in high demand, and many rainmakers are on the move.
  • Firms like SVB Leerink, JPMorgan, and Deutsche Bank are all poaching top talent.

Insider is tracking all of the big moves in the healthcare banking world>>

Advertisement


Inside Ginkgo's SPAC deal
Medical staff member prepares to administer the Moderna COVID-19 vaccine at the United Memorial Medical Center on December 21, 2020 in Houston, Texas.Go Nakamura/Getty Images

The US launches a one-of-a-kind trial to tell us whether mixing vaccine booster shots is a good idea

Find out more>>


More stories we're reading:


- Lydia

Advertisement
{{}}